The ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events) Study Group used a number of criteria to grade bleeding associated with heparin therapy.

Major bleeding:

(1) fatal bleeding

(2) symptomatic intracranial hemorrhage

(3) retroperitoneal hemorrhage

(4) intraocular hemorrhage leading to significant vision loss

(5) decrease in hemoglobin >= 3 g/dL

(6) need for red blood cell transfusion >= 2 units


Minor bleeding:

(1) all other clinically significant bleeding with one of the following:

(1a) interruption of anticoagulation therapy >= 24 hours

(1b) surgical intervention

(1c) transfusion of < 2 units of blood

To read more or access our algorithms and calculators, please log in or register.